Literature DB >> 32358041

Dietary Fiber Protects against Diabetic Nephropathy through Short-Chain Fatty Acid-Mediated Activation of G Protein-Coupled Receptors GPR43 and GPR109A.

Yan Jun Li1,2, Xiaochen Chen3, Tony K Kwan3, Yik Wen Loh3, Julian Singer3,2, Yunzi Liu3, Jin Ma1, Jian Tan4,5, Laurence Macia4,5, Charles R Mackay6, Steven J Chadban3,2,7, Huiling Wu1,2,7.   

Abstract

BACKGROUND: Studies have reported "dysbiotic" changes to gut microbiota, such as depletion of gut bacteria that produce short-chain fatty acids (SCFAs) through gut fermentation of fiber, in CKD and diabetes. Dietary fiber is associated with decreased inflammation and mortality in CKD, and SCFAs have been proposed to mediate this effect.
METHODS: To explore dietary fiber's effect on development of experimental diabetic nephropathy, we used streptozotocin to induce diabetes in wild-type C57BL/6 and knockout mice lacking the genes encoding G protein-coupled receptors GPR43 or GPR109A. Diabetic mice were randomized to high-fiber, normal chow, or zero-fiber diets, or SCFAs in drinking water. We used proton nuclear magnetic resonance spectroscopy for metabolic profiling and 16S ribosomal RNA sequencing to assess the gut microbiome.
RESULTS: Diabetic mice fed a high-fiber diet were significantly less likely to develop diabetic nephropathy, exhibiting less albuminuria, glomerular hypertrophy, podocyte injury, and interstitial fibrosis compared with diabetic controls fed normal chow or a zero-fiber diet. Fiber beneficially reshaped gut microbial ecology and improved dysbiosis, promoting expansion of SCFA-producing bacteria of the genera Prevotella and Bifidobacterium, which increased fecal and systemic SCFA concentrations. Fiber reduced expression of genes encoding inflammatory cytokines, chemokines, and fibrosis-promoting proteins in diabetic kidneys. SCFA-treated diabetic mice were protected from nephropathy, but not in the absence of GPR43 or GPR109A. In vitro, SCFAs modulated inflammation in renal tubular cells and podocytes under hyperglycemic conditions.
CONCLUSIONS: Dietary fiber protects against diabetic nephropathy through modulation of the gut microbiota, enrichment of SCFA-producing bacteria, and increased SCFA production. GPR43 and GPR109A are critical to SCFA-mediated protection against this condition. Interventions targeting the gut microbiota warrant further investigation as a novel renoprotective therapy in diabetic nephropathy.
Copyright © 2020 by the American Society of Nephrology.

Entities:  

Keywords:  chronic inflammation; diabetic nephropathy; metabolism

Mesh:

Substances:

Year:  2020        PMID: 32358041      PMCID: PMC7269358          DOI: 10.1681/ASN.2019101029

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  50 in total

1.  The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids.

Authors:  Andrew J Brown; Susan M Goldsworthy; Ashley A Barnes; Michelle M Eilert; Lili Tcheang; Dion Daniels; Alison I Muir; Mark J Wigglesworth; Ian Kinghorn; Neil J Fraser; Nicholas B Pike; Jay C Strum; Klaudia M Steplewski; Paul R Murdock; Julie C Holder; Fiona H Marshall; Philip G Szekeres; Shelagh Wilson; Diane M Ignar; Steve M Foord; Alan Wise; Simon J Dowell
Journal:  J Biol Chem       Date:  2002-12-19       Impact factor: 5.157

2.  Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome.

Authors:  Anne Vrieze; Els Van Nood; Frits Holleman; Jarkko Salojärvi; Ruud S Kootte; Joep F W M Bartelsman; Geesje M Dallinga-Thie; Mariette T Ackermans; Mireille J Serlie; Raish Oozeer; Muriel Derrien; Anne Druesne; Johan E T Van Hylckama Vlieg; Vincent W Bloks; Albert K Groen; Hans G H J Heilig; Erwin G Zoetendal; Erik S Stroes; Willem M de Vos; Joost B L Hoekstra; Max Nieuwdorp
Journal:  Gastroenterology       Date:  2012-06-20       Impact factor: 22.682

3.  Gut Bacteria Products Prevent AKI Induced by Ischemia-Reperfusion.

Authors:  Vinicius Andrade-Oliveira; Mariane T Amano; Matheus Correa-Costa; Angela Castoldi; Raphael J F Felizardo; Danilo C de Almeida; Enio J Bassi; Pedro M Moraes-Vieira; Meire I Hiyane; Andrea C D Rodas; Jean P S Peron; Cristhiane F Aguiar; Marlene A Reis; Willian R Ribeiro; Claudete J Valduga; Rui Curi; Marco Aurelio Ramirez Vinolo; Caroline M Ferreira; Niels Olsen Saraiva Câmara
Journal:  J Am Soc Nephrol       Date:  2015-01-14       Impact factor: 10.121

4.  Chronic kidney disease alters intestinal microbial flora.

Authors:  Nosratola D Vaziri; Jakk Wong; Madeleine Pahl; Yvette M Piceno; Jun Yuan; Todd Z DeSantis; Zhenmin Ni; Tien-Hung Nguyen; Gary L Andersen
Journal:  Kidney Int       Date:  2012-09-19       Impact factor: 10.612

Review 5.  The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease.

Authors:  Tao Yang; Elaine M Richards; Carl J Pepine; Mohan K Raizada
Journal:  Nat Rev Nephrol       Date:  2018-07       Impact factor: 28.314

6.  Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43.

Authors:  Kendle M Maslowski; Angelica T Vieira; Aylwin Ng; Jan Kranich; Frederic Sierro; Di Yu; Heidi C Schilter; Michael S Rolph; Fabienne Mackay; David Artis; Ramnik J Xavier; Mauro M Teixeira; Charles R Mackay
Journal:  Nature       Date:  2009-10-29       Impact factor: 49.962

7.  Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents.

Authors:  June Zhou; Roy J Martin; Richard T Tulley; Anne M Raggio; Kathleen L McCutcheon; Li Shen; Samuel Colby Danna; Sasmita Tripathy; Maren Hegsted; Michael J Keenan
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-09-16       Impact factor: 4.310

Review 8.  SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.

Authors:  Radica Z Alicic; Emily J Johnson; Katherine R Tuttle
Journal:  Am J Kidney Dis       Date:  2018-06-14       Impact factor: 8.860

9.  Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2.

Authors:  Gwen Tolhurst; Helen Heffron; Yu Shan Lam; Helen E Parker; Abdella M Habib; Eleftheria Diakogiannaki; Jennifer Cameron; Johannes Grosse; Frank Reimann; Fiona M Gribble
Journal:  Diabetes       Date:  2011-12-21       Impact factor: 9.461

10.  Identification and characterization of novel renal sensory receptors.

Authors:  Premraj Rajkumar; William H Aisenberg; Omar W Acres; Ryan J Protzko; Jennifer L Pluznick
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

View more
  42 in total

1.  Changes of gut microbiota in diabetic nephropathy and its effect on the progression of kidney injury.

Authors:  Kedan Cai; Yanhong Ma; Fanghao Cai; Xiaohan Huang; Liang Xiao; Chenyu Zhong; Pingping Ren; Qun Luo; Jianghua Chen; Fei Han
Journal:  Endocrine       Date:  2022-03-04       Impact factor: 3.633

2.  Short chain fatty acids for the risk of diabetic nephropathy in type 2 diabetes patients.

Authors:  Yang Li; Guo-Qiang Qin; Wan-Ying Wang; Xu Liu; Xiao-Qian Gao; Jun-Hui Liu; Tao Zheng; Wei Zhang; Lan Cheng; Kun Yang; Xin You; Yue Wu; Zhong-Ze Fang
Journal:  Acta Diabetol       Date:  2022-04-03       Impact factor: 4.280

3.  Renal Sensing of Bacterial Metabolites in the Gut-kidney Axis.

Authors:  Orestes Foresto-Neto; Bruno Ghirotto; Niels Olsen Saraiva Câmara
Journal:  Kidney360       Date:  2021-07-02

4.  Gut microbial products valerate and caproate predict renal outcome among the patients with biopsy-confirmed diabetic nephropathy.

Authors:  Chenyu Zhong; Xu Bai; Qinghuo Chen; Yanhong Ma; Jianhui Li; Jie Zhang; Qun Luo; Kedan Cai
Journal:  Acta Diabetol       Date:  2022-08-10       Impact factor: 4.087

Review 5.  Short-Chain Fatty Acid Receptors and Blood Pressure Regulation: Council on Hypertension Mid-Career Award for Research Excellence 2021.

Authors:  Jiaojiao Xu; Brittni N Moore; Jennifer L Pluznick
Journal:  Hypertension       Date:  2022-08-01       Impact factor: 9.897

Review 6.  Intestinal Flora: A Potential New Regulator of Cardiovascular Disease.

Authors:  Yifei Zou; Xianjing Song; Ning Liu; Wei Sun; Bin Liu
Journal:  Aging Dis       Date:  2022-06-01       Impact factor: 9.968

7.  Incidence of end-stage renal disease and risk factors for progression of renal dysfunction in Japanese patients with type 2 diabetes: the Fukuoka Diabetes Registry.

Authors:  Masanori Iwase; Hitoshi Ide; Toshiaki Ohkuma; Hiroki Fujii; Yuji Komorita; Masahito Yoshinari; Yutaro Oku; Taiki Higashi; Udai Nakamura; Takanari Kitazono
Journal:  Clin Exp Nephrol       Date:  2021-09-28       Impact factor: 2.801

Review 8.  Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders.

Authors:  Alexandros Marios Sofias; Federica De Lorenzi; Quim Peña; Armin Azadkhah Shalmani; Mihael Vucur; Jiong-Wei Wang; Fabian Kiessling; Yang Shi; Lorena Consolino; Gert Storm; Twan Lammers
Journal:  Adv Drug Deliv Rev       Date:  2021-06-15       Impact factor: 15.470

Review 9.  Roles of Gut Microbial Metabolites in Diabetic Kidney Disease.

Authors:  Qing Fang; Na Liu; Binjie Zheng; Fei Guo; Xiangchang Zeng; Xinyi Huang; Dongsheng Ouyang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-20       Impact factor: 5.555

Review 10.  Maternal microbiome in preeclampsia pathophysiology and implications on offspring health.

Authors:  Jeanne A Ishimwe
Journal:  Physiol Rep       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.